Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.44 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.44 |
| ▸ | CYP1B1 | Q16678 | 2/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.41 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.41 |
| ▸ | FYN | P06241 | 1/20 | 0.41 |
| ▸ | MAOA | P21397 | 1/20 | 0.41 |
| ▸ | ACHE | P22303 | 1/20 | 0.41 |
| ▸ | AHR | P35869 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 3/20 | 0.39 |
| ▸ | HPRT1 | P00492 | 3/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | CASP1 | P29466 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5445053 | 0.89 | HPRT1 (0.50) | ALDH1A1HSD17B10HIF1ACYP1B1CYP1A2 | |
| SCHEMBL4110292 | 0.84 | ALDH1A1 (0.36) | ALDH1A1HSD17B10HIF1ACYP1B1CYP1A2 | |
| SCHEMBL4722326 | 0.84 | ALDH1A1 (0.36) | ALDH1A1HSD17B10HIF1ACYP1B1CYP1A2 | |
| SCHEMBL8733681 | 0.83 | ALDH1A1 (0.35) | ALDH1A1HSD17B10HIF1ACYP1B1CYP1A2 | |
| SCHEMBL23803187 | 0.81 | HPRT1 (0.45) | ALDH1A1HSD17B10HIF1ACYP1B1CYP1A2 | |
| SCHEMBL291172 | 0.81 | ALDH1A1 (0.37) | ALDH1A1HSD17B10HIF1ACYP1B1CYP1A2 | |
| SCHEMBL9375653 | 0.80 | ALDH1A1 (0.37) | ALDH1A1HSD17B10HIF1ACYP1B1CYP1A2 | |
| SCHEMBL20774242 | 0.79 | HPRT1 (0.50) | ALDH1A1HSD17B10HIF1ACYP1B1CYP1A2 | |
| SCHEMBL441871 | 0.78 | ALDH1A1 (0.60) | ALDH1A1HSD17B10HIF1ACYP1B1CYP1A2 | |
| SCHEMBL29962858 | 0.78 | ALDH1A1 (0.60) | ALDH1A1HSD17B10HIF1ACYP1B1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 263 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11964943-B2 | 3,5-diarylidenyl-n-substituted-piperid-4-one-derived inhibitors of Stat3 pathway activity and uses thereof | KIAKOS KONSTANTINOS (AT) | 2024-04-23 | — | — | US | disclosed |
| EP-3223952-B1 | ENERGY INPUT DURING AGGLOMERATION FOR MAGNETIC SEPARATION | BASF SE (DE) | 2024-01-17 | — | — | EP | disclosed |
| CN-110249064-B | Use of copolymers as binders for pelletizing metal-containing ores | 巴斯夫欧洲公司 | 2022-01-28 | — | — | CN | disclosed |
| CN-108367300-B | Ultrafiltration of magnetically responsive support particles | 巴斯夫欧洲公司 | 2022-01-14 | — | — | CN | disclosed |
| EP-3344788-B1 | USE OF HYDROPHOBICALLY ASSOCIATING COPOLYMERS AS BINDERS FOR PELLETIZING METAL CONTAINING ORES | BASF SE (DE) | 2021-12-15 | — | — | EP | disclosed |
| US-20200399220-A1 | 3,5-DIARYLIDENYL-N-SUBSTITUTED-PIPERID-4-ONE-DERIVED INHIBITORS OF STAT3 PATHWAY ACTIVITY AND USES THEREOF | KIAKOS KONSTANTINOS (AT) | 2020-12-24 | — | — | US | disclosed |
| CN-107206392-B | Improvement of concentrate quality | 巴斯夫欧洲公司 | 2020-11-06 | — | — | CN | disclosed |
| WO-2019097080-A9 | 3,5-DIARYLIDENYL-N-SUBSTITUTED-PIPERID-4-ONE-DERIVED INHIBITORS OF STAT3 PATHWAY ACITIVTY AND USES THEROF | KIAKOS KONSTANTINOS (AT) | 2020-10-15 | — | — | WO | disclosed |
| EP-3713916-A1 | 3,5-DIARYLIDENYL-N-SUBSTITUTED-PIPERID-4-ONE-DERIVED INHIBITORS OF STAT3 PATHWAY ACITIVTY AND USES THEROF | Kiakos, Konstantinos (AT) | 2020-09-30 | — | — | EP | disclosed |
| EP-2880033-B1 | CYCLIC UREA- OR LACTAM-SUBSTITUTED QUINOXALINE-TYPE PIPERIDINE COMPOUNDS AND THE USES THEREOF | PURDUE PHARMA LP (US) | 2020-06-17 | — | — | EP | disclosed |
| WO-2004058754-A1 | BENZOAZOLYPIPERAZINE DERIVATIVES HAVING MGLUR1- AND MGLUR5-ANTAGONISTIC ACTIVITY | EURO-CELTIQUE S.A. (LU) | 2004-07-15 | — | — | WO | disclosed |
| US-20040127501-A1 | Therapeutic agents useful for treating pain | EURO-CELTIQUE S.A. (LU) | 2004-07-01 | — | — | US | disclosed |
| US-20040106625-A1 | cyanoiminopiperazines which inhibit vanilloid receptor 1 function in a cell | PURDUE PHARMA L.P. | 2004-06-03 | — | — | US | disclosed |
| WO-2004029031-A2 | THERAPEUTIC PIPERAZINE COMPOUNDS | EURO-CELTQUE, S.A. (LU) | 2004-04-08 | — | — | WO | disclosed |
| WO-2004029044-A1 | PYRIMIDINE COMPOUNDS AS THERAPEUTIC AGENTS | EURO-CELTIQUE, S.A. (LU) | 2004-04-08 | — | — | WO | disclosed |
| US-20040053914-A1 | Therapeutic agents useful for treating pain | PURDUE PHARMA L.P. | 2004-03-18 | — | — | US | disclosed |
| WO-2004011441-A1 | PYRIDAZINYLPIPERAZINE DERIVATIVES FOR TREATING PAIN | EURO-CELTIQUE S.A. (LU) | 2004-02-05 | — | — | WO | disclosed |
| WO-2004002983-A2 | THERAPEUTIC PIPERAZINE DERIVATIVES USEFUL FOR TREATING PAIN | EURO-CELTIQUE, S.A. (LU) | 2004-01-08 | — | — | WO | disclosed |
| WO-2003093236-A1 | 1-(PYRID-2-YL)-PIPERAZINE COMPOUNDS AS METABOTROPIC GLUTAMATE RECEPTOR INHIBITOR | EURO-CELTIQUE, S.A. (LU) | 2003-11-13 | — | — | WO | disclosed |
| EP-0321918-A2 | Process for the enzymatic racemate cleavage of racemic alcohols with/in vinyl esters by transesterification | HOECHST AKTIENGESELLSCHAFT (DE) | 1989-06-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040053914-A1 | Therapeutic agents useful for treating pain | SMN1; SMN2, OPRM1, PSEN1 | ALDH1A1 416/4885HSD17B10 2816/4885HIF1A 1087/4885 |
| US-20040127501-A1 | Therapeutic agents useful for treating pain | CACNA1A, GRIN2A, HTT | ALDH1A1 516/4885HSD17B10 2079/4885HIF1A 1463/4885 |
| US-11964943-B2 | 3,5-diarylidenyl-n-substituted-piperid-4-one-derived inhibitors of Stat3 pathway activity and uses thereof | STAT3, JAK2, STAT6 | ALDH1A1 928/4885HSD17B10 4013/4885HIF1A 1346/4885 |
| US-20040106625-A1 | cyanoiminopiperazines which inhibit vanilloid receptor 1 function in a cell | MC1R, MC5R, CHRNA5 | ALDH1A1 987/4885HSD17B10 1220/4885HIF1A 1305/4885 |
| US-20200399220-A1 | 3,5-DIARYLIDENYL-N-SUBSTITUTED-PIPERID-4-ONE-DERIVED INHIBITORS OF STAT3 PATHWAY ACTIVITY AND USES THEREOF | STAT3, JAK2, STAT6 | ALDH1A1 928/4885HSD17B10 4013/4885HIF1A 1346/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.